Brokers Offer Predictions for STOK Q3 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Research analysts at HC Wainwright issued their Q3 2025 EPS estimates for Stoke Therapeutics in a research report issued on Wednesday, March 19th. HC Wainwright analyst A. Fein expects that the company will earn ($0.55) per share for the quarter. HC Wainwright has a “Buy” rating and a $47.00 price objective on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.18) EPS, FY2026 earnings at ($2.87) EPS, FY2027 earnings at ($2.06) EPS, FY2028 earnings at ($1.21) EPS and FY2029 earnings at $0.22 EPS.

Several other analysts have also recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Chardan Capital reissued a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a research note on Wednesday. Finally, Needham & Company LLC reissued a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $23.00.

Stoke Therapeutics Trading Down 2.2 %

Shares of Stoke Therapeutics stock opened at $8.15 on Friday. The stock has a market capitalization of $431.68 million, a price-to-earnings ratio of -3.88 and a beta of 0.99. Stoke Therapeutics has a 1-year low of $5.93 and a 1-year high of $17.58. The firm’s 50-day moving average price is $9.47 and its two-hundred day moving average price is $11.45.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.38. The firm had revenue of $22.61 million for the quarter, compared to analysts’ expectations of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the transaction, the director now directly owns 148,253 shares of the company’s stock, valued at approximately $1,285,353.51. This trade represents a 6.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Barry Ticho sold 3,884 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the transaction, the insider now directly owns 63,962 shares in the company, valued at approximately $554,550.54. The trade was a 5.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,532 shares of company stock valued at $143,332. 11.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. KLP Kapitalforvaltning AS acquired a new stake in Stoke Therapeutics in the fourth quarter worth $63,000. Teacher Retirement System of Texas acquired a new stake in Stoke Therapeutics in the fourth quarter worth $113,000. China Universal Asset Management Co. Ltd. acquired a new stake in Stoke Therapeutics in the fourth quarter worth $124,000. Tower Research Capital LLC TRC raised its holdings in Stoke Therapeutics by 70.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock worth $132,000 after purchasing an additional 4,918 shares during the period. Finally, Invesco Ltd. acquired a new stake in Stoke Therapeutics in the fourth quarter worth $133,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.